Journal of Translational Autoimmunity最新文献

筛选
英文 中文
Ulcerative colitis with autoimmune thyroid disease results in bilateral auricular ossificans:a case 溃疡性结肠炎合并自身免疫性甲状腺疾病导致双侧耳廓骨化:一例
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-12-20 DOI: 10.1016/j.jtauto.2023.100225
Jiaqi Zhao , Fangxiao Liu , Lingshuo Bai , Zheng Jiao , Zihui Meng , Bo Jia , Yu Huang , Lin Liu
{"title":"Ulcerative colitis with autoimmune thyroid disease results in bilateral auricular ossificans:a case","authors":"Jiaqi Zhao ,&nbsp;Fangxiao Liu ,&nbsp;Lingshuo Bai ,&nbsp;Zheng Jiao ,&nbsp;Zihui Meng ,&nbsp;Bo Jia ,&nbsp;Yu Huang ,&nbsp;Lin Liu","doi":"10.1016/j.jtauto.2023.100225","DOIUrl":"10.1016/j.jtauto.2023.100225","url":null,"abstract":"<div><h3>Background</h3><p>Patients with ulcerative colitis (UC) often exhibit susceptibilities to multiple autoimmune diseases such as Sjogren's syndrome, primary sclerosing cholangitis, systemic lupus erythematosus, and insulin-dependent diabetes mellitus. This propensity likely stems from common pathogenic mechanisms underlying immune-mediated conditions. This report highlights the occurrence of autoimmune thyroid disease during UC exacerbations. Notably, the patient displayed petrified auricles.</p><p>Case Summary.</p><p>A 57-year-old male complained of sustained abdominal pain, diarrhea, hematochezia, and mucus for a duration of 20 days. The diagnosis of UC was confirmed via colonoscopy, histopathological examination, and small bowel MRE. Clinical evaluations revealed bilateral ectopic ossification in his ears, which appeared to develop over an unspecified timeframe. Imaging and histological evaluations substantiated the ectopic ossification diagnosis while eliminating the possibility of adrenal insufficiency. The presented case offers a unique instance of bilateral auricular ossification, which is hypothesized to result from hyperthyroidism.</p></div><div><h3>Conclusion</h3><p>Our case report underscores the necessity of enhancing awareness of the rare complications associated with UC. Medical practitioners should recognize the potential overlap of autoimmune thyroid disorders in UC patients. It is imperative to test for thyroid-related antibodies in such individuals, irrespective of overt thyroid dysfunction.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100225"},"PeriodicalIF":3.9,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909023000382/pdfft?md5=974b0c6db587f329ff0226c4277fe947&pid=1-s2.0-S2589909023000382-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of traditional therapeutics on prevalence and clinical outcomes of coronavirus disease 2019 in Chinese patients with autoimmune diseases 传统疗法对 2019 年中国自身免疫性疾病患者冠状病毒病发病率和临床结果的影响
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-12-12 DOI: 10.1016/j.jtauto.2023.100227
Saisai Huang , Xiaolei Ma , Juan Cao , Mengru Du , Zhiling Zhao , Dandan Wang , Xue Xu , Jun Liang , Lingyun Sun
{"title":"Effect of traditional therapeutics on prevalence and clinical outcomes of coronavirus disease 2019 in Chinese patients with autoimmune diseases","authors":"Saisai Huang ,&nbsp;Xiaolei Ma ,&nbsp;Juan Cao ,&nbsp;Mengru Du ,&nbsp;Zhiling Zhao ,&nbsp;Dandan Wang ,&nbsp;Xue Xu ,&nbsp;Jun Liang ,&nbsp;Lingyun Sun","doi":"10.1016/j.jtauto.2023.100227","DOIUrl":"https://doi.org/10.1016/j.jtauto.2023.100227","url":null,"abstract":"<div><p>The impact of the Coronavirus disease 2019 (COVID-19) pandemic on autoimmune diseases (AID) patients has been an important focus. This study was undertaken to characterize the incidence, clinical manifestations and hospitalization among AID affected by COVID-19 and to analyze the association between immunomodulatory medication and these outcomes. Clinical, demographic, maintenance treatment, symptoms and disease course data and outcomes of AID patients with COVID-19 infection were assessed via an online survey tool and printed copy from 1 January till February 28, 2023. A total of 432 patients with AID were enrolled in the study. The results showed the most common conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) was hydroxychloroquine (HCQ). The usage of csDMARDs didn't increase the risk of COVID-19 infection. Patients who warranted hospitalization were significantly older. ILD was associated with higher hospitalization rate. No csDMARDs other than calcineurin inhibitor (CNI) was associated with increased risk of hospitalization. HCQ intake was associated with cough. Compared with no glucocorticoids (GCs) group, high doses of GCs were accompanied with higher proportion of gastrointestinal symptoms and tachycardia, lower proportion of sore throat and ageusia. GCs didn't provoke the COVID‐19 infection in patients with AID, but chronic use of oral GCs was significantly more common in those requiring hospitalization, and higher dose of GCs were correlated with higher risk of hospitalization. 97 patients discontinued csDMARDs after infection, which resulted in an elevated risk of hospitalization. Meanwhile, withdrawal of csDMARDs was associated with higher odds of disease flare and lower proportion of remission than maintenance groups. Collectively, our analysis provides the evidence that maintenance treatment of csDMARDs may be more prudent for AID patients during COVID-19 pandemic.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100227"},"PeriodicalIF":3.9,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909023000400/pdfft?md5=c2b9a4279f81df0671e4b84d2422822a&pid=1-s2.0-S2589909023000400-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138656225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The autoimmune tautology revisited 自身免疫重言论
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-12-01 DOI: 10.1016/j.jtauto.2023.100204
Juan-Manuel Anaya, Santiago Beltrán
{"title":"The autoimmune tautology revisited","authors":"Juan-Manuel Anaya,&nbsp;Santiago Beltrán","doi":"10.1016/j.jtauto.2023.100204","DOIUrl":"10.1016/j.jtauto.2023.100204","url":null,"abstract":"","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"7 ","pages":"Article 100204"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909023000175/pdfft?md5=aef034a48774c20b443cb7b347a4a934&pid=1-s2.0-S2589909023000175-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47516650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the COVID-19 pandemic on temporal trends of biological indicators of autoimmunity COVID-19大流行对自身免疫生物学指标时间趋势的影响
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-12-01 DOI: 10.1016/j.jtauto.2023.100222
Elliott Van Regemorter , Giulia Zorzi , Anais Scohy , Damien Gruson , Johann Morelle
{"title":"Impact of the COVID-19 pandemic on temporal trends of biological indicators of autoimmunity","authors":"Elliott Van Regemorter ,&nbsp;Giulia Zorzi ,&nbsp;Anais Scohy ,&nbsp;Damien Gruson ,&nbsp;Johann Morelle","doi":"10.1016/j.jtauto.2023.100222","DOIUrl":"https://doi.org/10.1016/j.jtauto.2023.100222","url":null,"abstract":"<div><h3>Background and objective</h3><p>Coronavirus Disease 2019 (COVID-19) has been associated with the onset of autoimmune conditions, but whether this relationship is causal remains unknown, partly because robust evidence based on the detection of autoantibodies is lacking. This study explored the potential impact of COVID-19 pandemic on the temporal trends of autoimmunity.</p></div><div><h3>Methods</h3><p>Retrospective analysis of all consecutive autoimmune tests performed at one central laboratory at a University hospital, operating services for 18 other hospitals and clinical laboratories in Belgium, from January 01, 2015 to May 31, 2022. Longitudinal changes in the positivity rates of autoimmunity tests were analyzed, <em>i.e.</em> before and after the onset of the COVID-19 pandemic (March 11, 2020). The tests notably included the detection of autoantibodies associated with type 1 diabetes, thyroid diseases, connective tissue diseases, antiphospholipid syndrome, vasculitis and other organ-specific conditions. Kendall rank correlation test was applied to assess temporal trends.</p></div><div><h3>Results</h3><p>Over a period of 89 months, a total of 301,720 consecutive tests for 24 different autoantibodies among 87,674 unique patients were performed (87% adults, 68% women, mean age 44 ± 20 years). Overall, 52,862 (18%) tests returned positive, with positivity rates for each test ranging between 1% and 46%. No increase in the positivity rate of autoimmunity tests was observed after the start of the pandemic.</p></div><div><h3>Conclusion</h3><p>The onset of the COVID-19 pandemic was not associated with increased positivity rates of a large panel of autoimmune tests. Whether the higher incidence of autoimmune disorders associated with COVID-19 reflects detection bias or reverse causality, or is linked to seronegative autoimmune disorders requires further investigation.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"7 ","pages":"Article 100222"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909023000357/pdfft?md5=69b8ae4c90795eab3d7e3f98ac0994b8&pid=1-s2.0-S2589909023000357-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138475538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study 罕见和复杂结缔组织疾病患者接种COVID-19疫苗的长期结局:ERN-ReCONNET疫苗接种研究
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-12-01 DOI: 10.1016/j.jtauto.2023.100221
Chiara Tani , Chiara Cardelli , Roberto Depascale , Anna Gamba , Luca Iaccarino , Andrea Doria , Matilde Bandeira , Sara Paiva Dinis , Vasco C. Romão , Emanuele Gotelli , Sabrina Paolino , Maurizio Cutolo , Niccolò Di Giosaffatte , Alessandro Ferraris , Paola Grammatico , Lorenzo Cavagna , Veronica Codullo , Carlomaurizio Montecucco , Valentina Longo , Lorenzo Beretta , Marta Mosca
{"title":"Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study","authors":"Chiara Tani ,&nbsp;Chiara Cardelli ,&nbsp;Roberto Depascale ,&nbsp;Anna Gamba ,&nbsp;Luca Iaccarino ,&nbsp;Andrea Doria ,&nbsp;Matilde Bandeira ,&nbsp;Sara Paiva Dinis ,&nbsp;Vasco C. Romão ,&nbsp;Emanuele Gotelli ,&nbsp;Sabrina Paolino ,&nbsp;Maurizio Cutolo ,&nbsp;Niccolò Di Giosaffatte ,&nbsp;Alessandro Ferraris ,&nbsp;Paola Grammatico ,&nbsp;Lorenzo Cavagna ,&nbsp;Veronica Codullo ,&nbsp;Carlomaurizio Montecucco ,&nbsp;Valentina Longo ,&nbsp;Lorenzo Beretta ,&nbsp;Marta Mosca","doi":"10.1016/j.jtauto.2023.100221","DOIUrl":"https://doi.org/10.1016/j.jtauto.2023.100221","url":null,"abstract":"<div><h3>Background</h3><p>Vaccination is one of the most important measures to contain the COVID-19 pandemic, especially for frail patients. VACCINATE is a multicentre prospective observational study promoted by the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET) aimed at assessing the long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases (rcCTDs) in terms of efficacy and safety.</p></div><div><h3>Methods</h3><p>Adult rcCTDs patients were eligible for recruitment. Demographic, clinical and vaccination data were collected at enrolment. Follow-up visits were scheduled 4, 12, 24, 36 and 48 weeks after completion of the first vaccination cycle; data on adverse events, disease exacerbations and the occurrence of new SARS-CoV-2 infections were collected at these time-points.</p></div><div><h3>Findings</h3><p>365 rcCTDs patients (87 % female, mean age 51.8 ± 14.6 years) were recruited. Overall, 200 patients (54.8 %) experienced at least one adverse event, generally mild and in most cases occurring early after the vaccination. During follow-up, 55 disease exacerbations were recorded in 39 patients (10.7 %), distributed over the entire observation period, although most frequently within 4 weeks after completion of the vaccination cycle. The incidence of new SARS-CoV-2 infections was 8.9 per 1000 person-months, with no cases within 12 weeks from vaccine administration and an increasing trend of infections moving away from the primary vaccination cycle. Only one case of severe COVID-19 was reported during the study period.</p></div><div><h3>Interpretation</h3><p>COVID-19 vaccination seems effective and safe in rcCTDs patients. The rate of new infections was rather low and serious infections were uncommon in our cohort. No increased risk of disease flares was observed compared to previous disease history; however, such exacerbations may be potentially severe, emphasising the need for close monitoring of our patients.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"7 ","pages":"Article 100221"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909023000345/pdfft?md5=c233fe4841cd7c8163b927e103b556f6&pid=1-s2.0-S2589909023000345-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138502001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of imlifidase treatment on immunoglobulins in an HLA-hypersensitized lupus nephritis patient with anti-SSA/SSB antibodies after kidney transplantation: A case report 肾移植后抗 SSA/SSB 抗体的 HLA 超敏狼疮肾炎患者接受亚胺立酶治疗对免疫球蛋白的影响:病例报告
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-12-01 DOI: 10.1016/j.jtauto.2023.100223
Jean Milhès , Olivier Marion , Benedicte Puissant , Caroline Carlé , Charlène Bouthemy , Arnaud Del Bello , Nassim Kamar , Yves Renaudineau , Nicolas Congy-Jolivet
{"title":"Impact of imlifidase treatment on immunoglobulins in an HLA-hypersensitized lupus nephritis patient with anti-SSA/SSB antibodies after kidney transplantation: A case report","authors":"Jean Milhès ,&nbsp;Olivier Marion ,&nbsp;Benedicte Puissant ,&nbsp;Caroline Carlé ,&nbsp;Charlène Bouthemy ,&nbsp;Arnaud Del Bello ,&nbsp;Nassim Kamar ,&nbsp;Yves Renaudineau ,&nbsp;Nicolas Congy-Jolivet","doi":"10.1016/j.jtauto.2023.100223","DOIUrl":"https://doi.org/10.1016/j.jtauto.2023.100223","url":null,"abstract":"<div><p>Bacterial recombinant cysteine protease Ides (imlifidase, Idefirix®, Hansa Biopharma) is used to prevent humoral transplant rejection in highly HLA-sensitized recipients, and to control IgG-mediated autoimmune diseases. We report the case of a 51 years old woman suffering from lupus nephritis with end stage kidney disease, grafted for the second time and pre-treated with imlifidase. The patient was HLA-hypersensitized (calculated Panel Reactive Antibodies [Abs], cPRA&gt;99 %) and has three preformed Donor Specific Antibodies (DSA). Circulating immunoglobulins were monitored at initiation (0, 6, 36, 72 and 96 h), and at Ab recovery one and two months following imlifidase injection. From baseline, the higher depletion was reported after 36h for total IgG (−75 %) and IgG subclasses (−87 % for IgG1, IgG2 and IgG3, -78 % for IgG4), while no significant impact on IgA and IgM was observed. Anti-SSA 60 kDa and anti-SSB auto-Abs quickly decreased after imlifidase injection (−96 % for both after 36 h) as well as post-vaccinal specific IgG (−95 % for tetanus toxoid, −97 % for pneumococcus and −91 % for <em>Haemophilus influenzae</em> Abs after 36 h). At the Ab recovery phase, total IgG and anti-SSA60/SSB Abs reached their initial level at two months. Regarding alloreactive Abs, anti-HLA Abs including the three DSA showed a dramatic decrease after injection with 100 % depletion from baseline after 36 h as assessed by multiplex single bead antigen assay, leading to negative crossmatches using both lymphocytotoxicity (LCT) and flow cell techniques. DSA rebound at recovery was absent and remained under the positivity threshold (MFI = 1000) after 6 months. The findings from this case report are that imlifidase exerts an early depleting effect on all circulating IgG, while IgG recovery may depend in part from imlifidase's capacity to target memory B cells.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"7 ","pages":"Article 100223"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909023000369/pdfft?md5=5b5ce15ffb1c7ed2e62b6a9fcd812f7a&pid=1-s2.0-S2589909023000369-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138549360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver inflammation activity in patients with autoimmune hepatitis with normal alanine aminotransferase and immunoglobulin G levels 丙氨酸氨基转移酶和免疫球蛋白 G 水平正常的自身免疫性肝炎患者的肝脏炎症活性
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-11-28 DOI: 10.1016/j.jtauto.2023.100220
Yun Chen , Jiacheng Liu , Jian Wang , Weihua Wu , Huali Wang , Yilin Liu , Zhiyi Zhang , Shaoqiu Zhang , Yifan Pan , Yiguang Li , Weimao Ding , Li Zhu , Chuanwu Zhu , Jie Li , Yuanwang Qiu , Rui Huang , Chao Wu
{"title":"Liver inflammation activity in patients with autoimmune hepatitis with normal alanine aminotransferase and immunoglobulin G levels","authors":"Yun Chen ,&nbsp;Jiacheng Liu ,&nbsp;Jian Wang ,&nbsp;Weihua Wu ,&nbsp;Huali Wang ,&nbsp;Yilin Liu ,&nbsp;Zhiyi Zhang ,&nbsp;Shaoqiu Zhang ,&nbsp;Yifan Pan ,&nbsp;Yiguang Li ,&nbsp;Weimao Ding ,&nbsp;Li Zhu ,&nbsp;Chuanwu Zhu ,&nbsp;Jie Li ,&nbsp;Yuanwang Qiu ,&nbsp;Rui Huang ,&nbsp;Chao Wu","doi":"10.1016/j.jtauto.2023.100220","DOIUrl":"https://doi.org/10.1016/j.jtauto.2023.100220","url":null,"abstract":"<div><h3>Background and aims</h3><p>Normal serum transaminases and immunoglobulin G (IgG) levels are surrogate markers for hepatic histologic disease activity in autoimmune hepatitis (AIH). This study aimed to evaluate liver inflammation in patients with AIH with normal serum alanine aminotransferase (ALT) and IgG levels.</p></div><div><h3>Methods</h3><p>Two hundred and five AIH patients who underwent liver biopsy in four medical centers were included. Logistic regression analysis was used to identify risk factors associated with advanced inflammation.</p></div><div><h3>Results</h3><p>One hundred and thirty-one (63.9 %) AIH patients had advanced liver inflammation, and 108 (52.7 %) patients had advanced liver fibrosis. 60.0 % of patients with normal ALT and 51.7 % of patients with normal ALT and IgG had advanced inflammation. However, 76.7 % and 35.0 % of patients with or without advanced fibrosis with normal ALT had advanced inflammation, while the corresponding proportions of advanced inflammation were 78.6 % and 26.7 % in patients with normal ALT and IgG, respectively. Moreover, 81.0 % and 44.8 % of patients with and without cirrhosis with normal ALT had advanced inflammation, while the corresponding proportions were 83.3 % and 29.4 % in patients with normal ALT and IgG, respectively. Red cell distribution width (OR = 1.325, 95%CI 1.045–1.681, P = 0.020) and PT (OR = 1.514, 95%CI 1.138–2.014, P = 0.004) were independent factors associated with advanced inflammation.</p></div><div><h3>Conclusions</h3><p>High proportion of advanced inflammation was found in AIH patients with normal ALT and IgG levels despite without advanced fibrosis. Although using non-invasive methods may contribute to rule out liver fibrosis in AIH patients with normal ALT and IgG levels, liver biopsy is encouraged to assess liver inflammation.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"8 ","pages":"Article 100220"},"PeriodicalIF":3.9,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589909023000333/pdfft?md5=24ecc364b25e78fc6e1dc44a40b337eb&pid=1-s2.0-S2589909023000333-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138739167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SARS-CoV-2 and thyroid diseases SARS-CoV-2和甲状腺疾病
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-10-17 DOI: 10.1016/j.jtauto.2023.100214
Małgorzata Staruszkiewicz , Anna Pituch-Noworolska , Szymon Skoczen
{"title":"SARS-CoV-2 and thyroid diseases","authors":"Małgorzata Staruszkiewicz ,&nbsp;Anna Pituch-Noworolska ,&nbsp;Szymon Skoczen","doi":"10.1016/j.jtauto.2023.100214","DOIUrl":"https://doi.org/10.1016/j.jtauto.2023.100214","url":null,"abstract":"<div><p>SARS-CoV-2 virus responsible for acute respiratory disease affected other organs leading to co-existence symptoms or complications. Thyroid gland was one of them due to expression of angiotensin-converting enzyme 2 (ACE2), the protein facilitating viral binding to the host cells. Moreover, thyroid gland, important for regulation of hormonal network, is extremely sensitive to any changes in homeostasis and metabolism. It was shown, that COVID-19 was associated with induction of thyroid disease or increasing existing functional disturbances or autoimmune process. Thyroid diseases are mainly based on immunological pathomechanism although the relation between immune system and thyroid function is bidirectional e.g. thyroid hormones modulate specific immune responses, including cell-mediated immunity, NK cell activity, the production of antiviral interferon (IFN) and proliferation of T- and B-lymphocytes. The effects of COVID-19 and mRNA vaccine on thyroid function and diseases are discussed.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"7 ","pages":"Article 100214"},"PeriodicalIF":3.9,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49858292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accuracy of generative artificial intelligence models in differential diagnoses of familial Mediterranean fever and deficiency of Interleukin-1 receptor antagonist 生殖人工智能模型在家族性地中海热和白细胞介素-1受体拮抗剂缺乏鉴别诊断中的准确性
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-10-14 DOI: 10.1016/j.jtauto.2023.100213
Joshua Pillai , Kathryn Pillai
{"title":"Accuracy of generative artificial intelligence models in differential diagnoses of familial Mediterranean fever and deficiency of Interleukin-1 receptor antagonist","authors":"Joshua Pillai ,&nbsp;Kathryn Pillai","doi":"10.1016/j.jtauto.2023.100213","DOIUrl":"https://doi.org/10.1016/j.jtauto.2023.100213","url":null,"abstract":"<div><p>With the increasing development of artificial intelligence, large language models (LLMs) have been utilized to solve problems in natural language processing tasks. More recently, LLMs have shown unique potential in numerous applications within medicine but have been particularly investigated for their ability in clinical reasoning. Although the diagnostic accuracy of LLMs in forming differential diagnoses has been reviewed in general internal medicine applications, much is unknown in autoinflammatory disorders. From the nature of autoinflammatory diseases, forming a differential diagnosis is challenging due to the overlapping symptoms between disorders and even more difficult without genetic screening. In this work, the diagnostic accuracy of the Generative Pre-Trained Transformer Model-4 (GPT-4), GPT-3.5, and Large Language Model Meta AI (LLaMa) were evaluated in clinical vignettes of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) and Familial Mediterranean Fever (FMF). We then compared these models to a control group including one internal medicine physician. It was found that GPT-4 did not significantly differ in correctly identifying DIRA and FMF patients compared to the internist. However, the physician maintained a significantly higher accuracy than GPT-3.5 and LLaMa 2 for either disease. Overall, we explore and discuss the unique potential of LLMs in diagnostics for autoimmune diseases.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"7 ","pages":"Article 100213"},"PeriodicalIF":3.9,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49858293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Role of autoantibodies targeting interferon type 1 in COVID-19 severity: A systematic review and meta-analysis 靶向干扰素1型自身抗体在新冠肺炎严重程度中的作用:系统综述和荟萃分析。
IF 3.9
Journal of Translational Autoimmunity Pub Date : 2023-10-14 DOI: 10.1016/j.jtauto.2023.100219
Abolfazl Akbari , Alireza Hadizadeh , Mahdi Amiri , Neshat Najaf Najafi , Zahra Shahriari , Tannaz Jamialahmadi , Amirhossein Sahebkar
{"title":"Role of autoantibodies targeting interferon type 1 in COVID-19 severity: A systematic review and meta-analysis","authors":"Abolfazl Akbari ,&nbsp;Alireza Hadizadeh ,&nbsp;Mahdi Amiri ,&nbsp;Neshat Najaf Najafi ,&nbsp;Zahra Shahriari ,&nbsp;Tannaz Jamialahmadi ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.jtauto.2023.100219","DOIUrl":"10.1016/j.jtauto.2023.100219","url":null,"abstract":"<div><h3>Introduction</h3><p>Impairment of the type I interferon (IFN–I) signaling pathway is associated with increased severity of COVID-19 disease. Here we have undertaken a systematic review and meta = analysis on the association between the severity of COVID-19 and IFN-1 autoantibodies (AAbs; aIFN-1, aIFN-α, aIFN-ω, and aIFN-β).</p></div><div><h3>Methods</h3><p>Four databases, including Medline [PubMed], Embase, Web of Science, and Scopus, were systematically searched to find papers on the role of aIFN-1 and its subtype AAbs in the severity of COVID-19 infection. Data on the prevalence of aIFN-1, aIFN-α, aIFN-ω, and aIFN-β were pooled using random- or fixed-effects models. Subgroup analysis was performed based on disease severity. Odds ratios (OR) for COVID-19 disease outcome, including length of hospital stay, ICU admission and death, were calculated in relation to positive or negative plasma IFN-1 AAbs.</p></div><div><h3>Results</h3><p>A total of 33 studies with 13023 patients were included. The overall prevalence of circulating aIFN-1, aIFN-α, and aIFN-ω AAbs was 17.8 % [13.8, 22.8], 7.2 % [4.7, 10.9], and 4.4 % [2.1, 8.6], respectively, and the overall prevalence of neutralizing aIFN-1, aIFN-α, aIFN-ω, and aIFN-β AAbs was 7.1 % [4.9, 10.1], 7.5 % [5.9, 9.5], 8.0 % [5.7, 11.1] and 1.2 % [0.4, 3.5], respectively. Circulating aIFN-α (OR = 4.537 [2.247, 9.158]), neutralizing aIFN-α (O = 17.482 [8.899, 34.342]), and neutralizing aIFN-ω (OR = 12.529 [7.397, 21.222]) were significantly more frequent in critical/severe patients than in moderate/mild patients (p &lt; 0.001 for all). Anti–IFN–1 was more common in male subjects (OR = 2.248 [1.366, 3.699], p = 0.001) and two COVID-19 outcomes including ICU admission (OR = 2.485 [1.409, 4.385], p = 0.002) and death (OR = 2.593 [1.199, 5.604], p = 0.015) occurred more frequently in patients with positive anti–IFN–1.</p><p>Conclusion: aIFN-1 and its subtypes AAbs are associated with severe and critical COVID-19 disease and may be a predictive marker for a poor prognosis, particularly in men.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"7 ","pages":"Article 100219"},"PeriodicalIF":3.9,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49692812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信